Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912108 | 0.71 | CRBN (0.36) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| Hydrochloric Acid SCHEMBL3219393 | 0.70 | KDM4E (0.37) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL23970500 | 0.69 | — | — | |
| SCHEMBL18096285 | 0.67 | CACNA1H (0.33) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL18650805 | 0.67 | PDE4A (0.33) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL3069788 | 0.64 | ALDH1A1 (0.40) | KDM4EALDH1A1HPGDHIF1A | |
| SCHEMBL3546635 | 0.63 | CACNA1H (0.39) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL3553474 | 0.62 | KMT2A (0.47) | KDM4EALDH1A1CACNA1H | |
| SCHEMBL24700453 | 0.62 | DDB1 (0.47) | KDM4E | |
| SCHEMBL15657996 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | IRAK2, IRAK3, IRAK1 | PDE4A 1421/4885PDE4B 1535/4885PDE4C 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.